Quantcast
Last updated on April 17, 2014 at 16:26 EDT

Latest Destination Therapy Stories

2013-11-25 16:27:05

FRAMINGHAM, Mass., Nov. 25, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference at 2:00 p.m. ET on Tuesday, December 3, 2013. The conference is being held December 3-4 at the Palace Hotel in New York City....

2013-11-18 23:21:48

New Study Results Presented at AHA Scientific Sessions 2013 Show a Single Dose of Stem Cell Therapy During Surgery May Improve New LVAD Patients’ Heart Function New York, New York (PRWEB) November 18, 2013 A multicenter team of researchers within the NIH-funded Cardiothoracic Surgical Trials Network (CTSN), led by Icahn School of Medicine at Mount Sinai, have found end-stage heart failure patients who receive a surgically implanted left ventricular assist device (LVAD) heart pump may...

2013-11-08 16:24:49

FRAMINGHAM, Mass., Nov. 8, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum at 1:30 p.m. ET on Thursday, November 14, 2013. The one-day conference is being held at the Westin Grand...

2013-11-05 16:27:53

FRAMINGHAM, Mass., Nov. 5, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 10:30 a.m. MST. The conference will be held November 11-14 at the Phoenician Hotel in Scottsdale,...

2013-10-17 23:28:38

Global LVAD Market Report: 2013 Edition and Robotic Surgery Market Report: 2013 Edition are the new research reports available with MarketReportsOnline.com. Dallas, Texas (PRWEB) October 17, 2013 LVADs are the mechanical devices which are implanted into the abdomen or chest and attached to a weakened heart to help it pump. LVADs are now sometimes used as an alternative to transplantation. LVAD is suitable for bridge-to-transplant market, which extends the patient’s life until a suitable...

2013-08-27 08:28:21

- Amended protocol includes enhanced blood pressure monitoring to ensure optimal patient management - FRAMINGHAM, Mass. and SYDNEY, Aug. 27, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption)...

2013-08-09 16:22:31

FRAMINGHAM, Mass. and SYDNEY, Aug. 9, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2013 Annual Growth Conference at 3:00 p.m. EDT on Wednesday, August 14, 2013. The conference is being held August 14-15 at the The...

2013-07-01 08:27:15

PLEASANTON, Calif., July 1, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it has acquired the DuraHeart(®) II ("DH-II") ventricular assist system from Terumo Corporation (TSE: 4543 Section 1) for an upfront cash payment of $13 million and potential future milestone payments, based on regulatory approvals and product sales, of up to $43.5...

2013-06-17 08:29:28

- Amended protocol includes enhanced blood pressure monitoring to ensure optimal patient management - FRAMINGHAM, Mass., and SYDNEY, June 17, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval to an IDE...

2013-06-13 08:28:38

FRAMINGHAM, Mass. and SYDNEY, June 13, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference at 9:25 a.m. EDT on Tuesday, June 18, 2013. The conference is being held June 18-19 at...